Altimmune (ALT) Competitors $3.93 0.00 (0.00%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$3.96 +0.03 (+0.89%) As of 10/8/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALT vs. AMLX, XERS, SION, ZYME, LENZ, ATAI, DNTH, PHVS, EVO, and AMPHShould you be buying Altimmune stock or one of its competitors? The main competitors of Altimmune include Amylyx Pharmaceuticals (AMLX), Xeris Biopharma (XERS), Sionna Therapeutics (SION), Zymeworks (ZYME), LENZ Therapeutics (LENZ), atai Life Sciences (ATAI), Dianthus Therapeutics (DNTH), Pharvaris (PHVS), Evotec (EVO), and Amphastar Pharmaceuticals (AMPH). These companies are all part of the "pharmaceutical products" industry. Altimmune vs. Its Competitors Amylyx Pharmaceuticals Xeris Biopharma Sionna Therapeutics Zymeworks LENZ Therapeutics atai Life Sciences Dianthus Therapeutics Pharvaris Evotec Amphastar Pharmaceuticals Amylyx Pharmaceuticals (NASDAQ:AMLX) and Altimmune (NASDAQ:ALT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends. Which has preferable valuation and earnings, AMLX or ALT? Altimmune has higher revenue and earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmylyx Pharmaceuticals-$249K-4,827.19-$301.74M-$2.50-5.39Altimmune$20K17,343.09-$95.06M-$1.18-3.33 Do analysts prefer AMLX or ALT? Amylyx Pharmaceuticals currently has a consensus target price of $14.75, indicating a potential upside of 9.42%. Altimmune has a consensus target price of $17.40, indicating a potential upside of 342.75%. Given Altimmune's higher possible upside, analysts clearly believe Altimmune is more favorable than Amylyx Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amylyx Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 2.86Altimmune 2 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.38 Does the media favor AMLX or ALT? In the previous week, Altimmune had 1 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 20 mentions for Altimmune and 19 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 0.23 beat Altimmune's score of 0.05 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amylyx Pharmaceuticals 6 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Altimmune 2 Very Positive mention(s) 2 Positive mention(s) 13 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Do insiders and institutionals believe in AMLX or ALT? 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 78.1% of Altimmune shares are owned by institutional investors. 12.3% of Amylyx Pharmaceuticals shares are owned by insiders. Comparatively, 4.4% of Altimmune shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is AMLX or ALT more profitable? Amylyx Pharmaceuticals has a net margin of 0.00% compared to Altimmune's net margin of -438,730.03%. Altimmune's return on equity of -62.63% beat Amylyx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Amylyx PharmaceuticalsN/A -82.48% -70.15% Altimmune -438,730.03%-62.63%-55.29% Which has more volatility and risk, AMLX or ALT? Amylyx Pharmaceuticals has a beta of -0.33, suggesting that its stock price is 133% less volatile than the S&P 500. Comparatively, Altimmune has a beta of 0.07, suggesting that its stock price is 93% less volatile than the S&P 500. SummaryAltimmune beats Amylyx Pharmaceuticals on 10 of the 17 factors compared between the two stocks. Get Altimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALT vs. The Competition Export to ExcelMetricAltimmuneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$346.85M$2.64B$6.10B$10.55BDividend YieldN/A56.71%5.69%4.75%P/E Ratio-3.3323.6985.4727.60Price / Sales17,343.09556.27582.22224.03Price / CashN/A173.2337.9261.55Price / Book2.265.5313.136.76Net Income-$95.06M$32.78M$3.30B$275.88M7 Day PerformanceN/A5.82%4.29%2.81%1 Month Performance3.97%13.16%9.45%9.24%1 Year Performance-35.68%1.69%86.64%35.42% Altimmune Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALTAltimmune3.0641 of 5 stars$3.93flat$17.40+342.7%-37.0%$346.85M$20K-3.3350Analyst ForecastHigh Trading VolumeAMLXAmylyx Pharmaceuticals2.1479 of 5 stars$14.90+2.6%$14.50-2.7%+313.5%$1.33B$87.37M-5.96200Analyst ForecastXERSXeris Biopharma2.8562 of 5 stars$8.08-1.2%$7.08-12.3%+178.9%$1.30B$203.07M-38.47290News CoveragePositive NewsAnalyst ForecastSIONSionna Therapeutics2.8049 of 5 stars$29.52+2.0%$38.00+28.7%N/A$1.30BN/A0.0035Analyst ForecastInsider TradeHigh Trading VolumeZYMEZymeworks0.074 of 5 stars$17.23+3.8%N/AN/A$1.30B$76.30M-17.76460News CoverageAnalyst ForecastLENZLENZ Therapeutics0.5624 of 5 stars$44.89+6.8%$49.60+10.5%+99.1%$1.28BN/A-23.63110Positive NewsAnalyst ForecastATAIatai Life Sciences3.3719 of 5 stars$5.45+3.4%$11.25+106.4%+393.8%$1.27B$310K-7.9080Positive NewsAnalyst ForecastDNTHDianthus Therapeutics2.9355 of 5 stars$39.55+7.7%$61.57+55.7%+24.2%$1.27B$6.24M-12.1780Analyst ForecastHigh Trading VolumePHVSPharvaris2.2149 of 5 stars$24.26+0.4%$34.00+40.1%+28.4%$1.27BN/A-7.2230Positive NewsAnalyst ForecastHigh Trading VolumeEVOEvotec1.5948 of 5 stars$3.54+1.7%$5.40+52.5%+22.1%$1.26B$862.40M0.004,827News CoverageAnalyst ForecastAMPHAmphastar Pharmaceuticals4.4995 of 5 stars$26.92+0.3%$31.60+17.4%-43.9%$1.25B$731.97M10.082,028Positive NewsAnalyst Forecast Related Companies and Tools Related Companies Amylyx Pharmaceuticals Alternatives Xeris Biopharma Alternatives Sionna Therapeutics Alternatives Zymeworks Alternatives LENZ Therapeutics Alternatives atai Life Sciences Alternatives Dianthus Therapeutics Alternatives Pharvaris Alternatives Evotec Alternatives Amphastar Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALT) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Altimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Altimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
